reasoned that genes that were commonly prognostic in highly correlated cancers revealed by 23
Spearman's correlation analysis could be harnessed as a molecular signature for risk 24 assessment. A 10-gene signature, uniting prognostic genes that were common in highly 25 correlated cancers, was significantly associated with overall survival in patients with clear cell 26 renal cell (P<0.0001), papillary renal cell (P=0.0007), liver (P=0.002), lung (P=0.028), pancreas 27 (P=0.00013) or endometrial (P=0.00063) cancers. Receiver operating characteristic analyses 28
revealed that a combined model of the 10-gene signature and tumor staging outperformed 29 either classifiers when considered alone. Multivariate Cox regression models incorporating 30 additional clinicopathological features revealed that the signature was an independent 31 predictor of overall survival. Tumor hypoxia is associated with adverse outcomes. Consistent 32 across all six cancers, patients with high 10-gene and high hypoxia scores had significantly 33 higher mortality rates compared to those with low 10-gene and low hypoxia scores. Functional 34 enrichment analyses revealed that high mortality rates in patients with high 10-gene scores 35
were attributable to an overproliferation phenotype. Death risk in these patients was further 36 exacerbated by concurrent mutations of a cell cycle checkpoint protein, TP53. The 10-gene signature identified tumors with heightened DNA repair ability. This information has the 38 potential to radically change prognosis through the use of adjuvant DNA repair inhibitors with 39 chemotherapeutic drugs. 40
[298 words] 41
Introduction 47 48 Genetic material must be transmitted in its original, unaltered form during cell division. 49
However, DNA faces continuous assaults from both endogenous and environmental agents 50 contributing to the formation of permanent lesions and cell death. To overcome DNA damage 51 threats, living systems have evolved highly coordinated cellular machineries to detect and 52 repair damages as they occur. However, DNA repair mechanisms and consequently DNA 53 damage responses (DDR) are often deregulated in cancer cells and such aberrations may 54 contribute to cancer progression and influence prognosis. Overexpression of DNA repair genes 55 allow tumor cells to overcome the cytotoxic effects of radiotherapy and chemotherapy. As 56 such, inhibitors of DNA repair can increase the vulnerability of tumor cells to chemotherapeutic 57 drugs by preventing the repair of deleterious lesions 1 . 58
59
There are six main DNA repair pathways in mammalian cells. Single-strand DNA damage are 60 repaired by the base excision repair (BER), nucleotide excision repair (NER) and mismatch 61 repair (MR) pathways. The poly(ADP-ribose) polymerase (PARP) gene family encodes key 62 players of the BER pathway involved in repairing damages induced by ionizing radiation and 63 alkylating agents 2,3 . Replication errors are corrected by the MR pathway while the NER 64 pathway is responsible for removing bulky intercalating agents 4,5 . Tumor cells with deficiencies 65 in the NER pathway have increased sensitivity to platinum-based chemotherapeutic drugs 66 (cisplatin, oxaliplatin etc.) 6,7 . Double-strand breaks induced by ionizing radiation are more 67 difficult to repair and thus are highly cytotoxic. Dysregulation of genes involved in the 68 homology-directed repair (HDR), non-homologous end joining (NHEJ) and Fanconi anemia (FA) 69 pathways are associated with altered repair of double-strand breaks. 70
Patients were median dichotomized into low-and high-score groups based on their 10-gene 116 scores in each cancer type. Differential expression analyses were performed using the linear 117 model and Bayes method executed by the limma package in R. P values were adjusted using 118 the Benjamini-Hochberg false discovery rate procedure. We considered genes with log2 fold 119 change of > 1 or < -1 and adjusted P-values < 0.05 as significantly differentially expressed 120 between the two patient groups. To determine which biological pathways were significantly enriched, differentially expressed 125 genes were mapped against the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and 126 Genomes (KEGG) databases using GeneCodis 13 . The Enrichr tool was used to investigate 127 transcription factor protein-protein interactions that were associated with the differentially 128 expressed genes 14, 15 . 129 130 131
Survival analysis 132
Univariate Cox proportional hazards regression analyses were performed using the R survival 133
and survminer packages to determine if expression levels of individual DNA repair genes as 134 well as those of the 10-gene scores were significantly associated with overall survival. 135
Multivariate Cox regression was employed to determine the influence of additional clinical 136 variables on the 10-gene signature. Hazard ratios (HR) and confidence intervals were 137 determined from the Cox models. HR greater than one indicated that a covariate was positively 138 associated with even probability or increased hazard and negatively associated with survival 139 duration. Non-significant relationship between scaled Schoenfeld residuals supported the 140 proportional hazards assumption in the Cox model. Both survival and survminer packages were 141 also used for Kaplan-Meier analyses and log-rank tests. For Kaplan-Meier analyses, patients 142 were median dichotomized into high-and low-score groups using the 10-gene signature. To 143 determine the predictive performance (specificity and sensitivity) of the signature in relation 144 to tumor staging parameters, we employed the receiver operating characteristic (ROC) analysis 145 implemented by the R survcomp package, which also calculates area under the curve (AUC) 146 values. AUC values can fall between 1 (perfect marker) and 0.5 (uninformative marker). 147 148 TP53 mutation analysis 149 TCGA mutation datasets (Level 3) were retrieved from GDAC Firehose to annotate patients 150 with mutant TP53. To ascertain the association of TP53 mutation with the 10-gene signature 151 on overall survival, we employed the Kaplan-Meier analysis and log-rank tests implemented in 152
R. 153 154
All plots were generated using R pheatmap and ggplot2 packages 16 . Venn diagram was 155 generated using the InteractiVenn tool 17 . Results 
158
Prognosis of DNA repair genes in 16 cancer types and the development of a 10-gene signature 159 A total of 187 genes associated with six DDR pathways found in mammalian cells were curated: 160 BER (33 genes), MR (23 genes), NER (39 genes), HDR (26 genes), NHEJ (13 genes) and FA (53 161 genes) 18 ( Fig. 1 , Table S1 ). Of the 187 genes, 49 were represented in two or more pathways, 162 yielding 138 non-redundant candidates. To determine which of the 138 DNA repair genes 163 conferred prognostic information, we employed Cox proportional hazards regression on all 164 genes individually on 16 cancer types to collectively include 16,225 patients 11 (Table S2 ). In 165 clear cell renal cell carcinoma, 81 genes were found to be significantly associated with overall 166 survival; this cancer had the highest number of prognostic DNA repair genes (Table S3 ). This is 167 followed by 54, 53, 46, 44 and 33 prognostic genes in cancers of the pancreas, papillary renal 168 cell, liver, lung and endometrium respectively (Table S3 ). In contrast, cancers of the brain 169 (glioblastoma: 2 genes), breast (5 genes), cervix (6 genes) and esophagus (7 genes) had some 170 of the lowest number of prognostic DNA repair genes (Table S3 ), suggesting that there is a 171 significant degree of variation in the contribution of DNA repair genes in predicting survival 172 outcomes. Spearman's rank-order correlation analysis revealed a hub of five highly correlated 173 cancers (lung, papillary renal cell, pancreas, liver and endometrium), indicating that a good 174 number of prognostic DNA repair genes were shared between these cancers (Spearman's 175 rho=0.21 to 0.44) ( Fig. S1 ). We rationalized that prognostic genes that are common in these 176 highly correlated cancers could form a new multigenic risk assessment classifier. Ten genes 177 were prognostic in the five highly correlated cancers: PRKDC (NHEJ), NEIL3 (BER), FANCD2 (FA), 178 BRCA2 (HDR and FA), EXO1 (MR), XRCC2 (HDR), RFC4 (MR and NER), USP1 (FA), UBE2T (FA) and 179 FAAP24 (FA), which, interestingly, represent members from all six DDR pathways. 180 would thus be an attractive measure to limit tumor cell proliferation. This has led to the 277 development of numerous CDK inhibitors as anticancer agents 26, 27 . DNA repair is tightly 278 coordinated with cell cycle progression. Certain DNA repair mechanisms are dampened in non-279 proliferating cells, while repair pathways are often perturbed during tumor development. 280
Perturbation can take the form of defective DNA repair or over-compensation of a pathway 281 arising from defects in another pathway 28 . As a result, DNA repair inhibitors could prevent the 282 repair of lesions induced by chemotherapeutic drugs to trigger apoptosis and to enhance the 283 elimination of tumor cells. 284
285
We rationalize that patients with high 10-gene scores would have heightened ability for DNA 286 repair thus allowing tumor cells to progress through the cell cycle and continue to proliferate. 287
Using Spearman's rank-order correlation, we observed that the expression of each of the 10 288 signature genes were positively correlated with the expression of genes involved in cell cycle 289 progression (cyclins and CDKs) and negatively correlated with genes involved in cell cycle arrest 290 (CDK inhibitors) ( Fig. 6A ). Interestingly, the patterns of correlation were remarkably similar 291 across all six cancer types, implying that elevated expression of DNA repair genes is associated 292 with a hyper-proliferative phenotype. We next asked whether patients within the high 10-gene 293 score category had an overrepresentation of processes associated with cell cycle dysregulation 294 as this could provide an explanation on the elevated mortality risks in these patients. To answer 295 this, we divided patients from each of the six cancer types into two groups (high score and low 296 score) based on the mean expression of the 10 signature genes using the 50 th percentile cut-297 off. Differential expression analyses between the high-and low-score groups revealed that 298 394, 425, 1259, 1279, 714 and 977 genes were differentially expressed (-1 > log2 fold-change 299 > 1, P<0.05) in clear cell renal cell, papillary renal cell, liver, lung, pancreas and endometrial 300 cancers respectively (Table S4) . 301
302
Analyses of biological functions of these genes revealed functional enrichment of ontologies 303 associated with cell division, mitosis, cell cycle, cell proliferation, DNA replication and 304 homologous recombination consistent in all six cancer types ( Fig. 6B ). This suggests that the 305 significantly higher mortality rates in patients with high 10-gene scores were due to enhanced 306 tumor cell proliferation exacerbated by the ability of these cells to repair DNA lesions as they 307 arise. Additional ontologies related to tumorigenesis such as PPAR and TP53 signaling were 308 also associated with poor prognosis (Fig. 6B ). A total of 87 differentially expressed genes (DEGs) 309
were found to be in common in all six cancer types ( Fig. S3 ) (Table S5 ). To dissect the underlying 310 biological roles of the 87 DEGs at the protein level, we evaluated the enrichment of 311 transcription factor protein-protein interactions using the Enrichr platform 14 .TP53 represents 312 the most enriched transcription factor involved in the regulation of the DEGs as evidenced by 313 the highest combined score, which takes into account both Z score and P value (Table S6) An important role of TP53 is its tumor suppressive function through TP53-mediated cell cycle 322 arrest and apoptosis 29 . Hence, somatic mutations in TP53 can confer tumor cells with growth advantage and indeed, this is a well-known phenomenon in many cancers [30] [31] [32] . We rationalized 324 that TP53 deficiency resulting in defective checkpoint may synergize with the overexpression 325 of DNA repair genes to prevent growth arrest and promote tumor proliferation. To test this 326 hypothesis, we examined TP53 mutation status in all six cancer types and observed that TP53 327 mutation frequency was the highest in pancreatic cancer patients (58%) followed by lung 328 cancer (57%), endometrial cancer (21%), liver cancer (16%), papillary renal cell (1.8%) and clear 329 cell renal cell (1.2%) (Table S7 ). Cancers with TP53 mutation frequency of at least 10% were 330 selected for survival analyses. Univariate Cox regression analyses revealed that TP53 mutation 331 status only conferred prognostic information in pancreatic (HR=1.657, P=0.044), endometrial 332 (HR=1.780, P=0.041) and liver (HR=2.603, P<0.0001) cancers but not in lung cancer (HR=1.428, 333 P=0.056) ( Table 1 ). Cancers where TP53 mutation offered predictive value were taken forward 334 for analyses in relation to the 10-gene signature. Cox regression analyses revealed that a 335 combination of TP53 mutation and high 10-gene score resulted in significantly higher risk of 336 death (Table 3 ; Fig. 6C ). Survival rates were significantly diminished in patients harboring high 337 10-gene scores and the mutant variant of TP53 compared to those with low 10-gene scores 338 and wild-type TP53: liver (HR=3.876, P<0.0001), pancreas (HR=4.881, P=0.0002) and 339 endometrium (HR=3.719, P=0.00028) ( Table 3 ; Fig. 6C ). Moreover, in multivariate Cox models 340 involving TNM staging and TP53 mutation status, the 10-gene signature remained a significant 341 prognostic factor (Table 1) . This suggests that although the 10-gene signature provided 342 additional resolution in risk assessment when used in combination with TP53 mutation status, 343 its function is independent. However, in the multivariate model TP53 was significant only in 344 liver cancer (HR=2.085, P=0.0044), suggesting that TP53 mutation was not independent of the 345 signature or TNM staging in pancreatic and endometrial cancers (Table 1) . Overall, the results 346 suggest that defects in cell cycle checkpoint combined with augmented DNA repair ability were adverse risk factors contributing to poor prognosis. Both TP53 mutation status and 10-gene 348 scores could offer additional predictive value in risk assessment by further delineation of 349 patients into additional risk groups. 350
Discussion and Conclusion 352 353
We systematically examined the associations between the expression patterns of 138 DNA 354 repair genes in 16 cancer types and prognosis. Our pan-cancer multigenic approach revealed 355 genes that work synergistically across cancers to inform patient prognosis that would 356 otherwise remain undetected in analysis involving a single gene or a single cancer type. We 357 developed a 10-gene signature that incorporates the expression profiles of 10 highly correlated 358 DNA repair genes for use as risk predictors in six cancer types (n=2,257). This signature offers 359 a more precise discrimination of patient risk groups in these six cancers where high expression 360
of signature genes is associated with poor survival outcomes. Importantly, we demonstrated 361 that the signature can improve the prognostic discrimination of TNM when used as a combined 362 model, which is particularly useful to allow further stratification of patients within similar TNM 363 stage groups (Fig. 4) . 364 365 Intrinsic differences in DNA repair machineries in cancer cells may pose a significant challenge 366 to successful therapy. Mutations in DNA repair genes allow the generation of persistent DNA 367 lesions that would otherwise be repaired. Germline mutations of DNA repair genes are linked 368 to increased genome instability and cancer risks 33 and abrogation of genes in one DNA repair 369 pathway can be compensated by another pathway 1 . BRCA1 and BRCA2 mutations sensitize 370 cells to PARP1 inhibition, a protein involved in the BER pathway 10 . Since BRCA1 and BRCA2 are 371 important for homology-directed repair, PARP1 inhibition in BRCA1/2-defective cells would 372 result in dysfunctional HDR and BER pathways preventing lesion repair and thus leading to 373 apoptosis 10 . 374
In addition to genetic polymorphism, upregulation of DNA repair genes in tumors could 376 promote resistance to radiotherapy and chemotherapy as the cells would have enhanced 377 ability to repair cytotoxic lesions induced by these therapies. Overexpression of ERCC1 involved 378 in the NER pathway in non-small-cell lung cancer is linked to poor survival in cisplatin-treated 379 patients 7 . The 1,2-d(GpG) cross-link lesion generated by cisplatin treatment is readily repaired 380 by the NER pathway, hence ERCC1 overexpression would promote cisplatin resistance. Low 381
MGMT expression in astrocytoma is associated with longer survival outcomes in patients 382 treated with temozolomide 34 ; an observation that is consistent with the role of MGMT in 383 repairing lesions caused by temozolomide thus allowing MGMT deficient tumor cells to 384 accumulate enough unrepairable damage. TP53 plays essential roles in cell-cycle arrest and 385 apoptosis through the activation of checkpoint genes 29 . We show that patients with high 10-386 gene scores that concurrently have mutant TP53 exhibited significantly higher mortality rates 387 ( Fig. 6C ), suggesting that defects in cell cycle checkpoint coupled with an increase propensity 388 for DNA repair may lead to dramatically poorer outcomes. 389
390
Multiple studies have reported the associations between dysfunctional DNA repair pathways 391 and cancer, but most of these studies are restricted to investigations on a limited number of 392 genes and on one cancer at a time. One of the key advantages of our study is that it is an 393 unbiased exploration transcending the candidate-gene approach that takes into account the 394 multifaceted interplay of DNA repair genes in diverse cancer types. We rationalize that since 395 ionizing radiation and chemotherapy are the main treatment options currently available for 396 cancer patients, a molecular signature capable of discriminating patients with increased 397 expression of DNA repair genes that would benefit from adjuvant therapy through 398 pharmacological inhibition of DNA repair to overall improve therapeutic outcomes. 399 400 Tumor hypoxia is also a well-known cause of therapy resistance. A notable finding of our study 401 is that patients having both high 10-gene and hypoxia scores had significantly poorer survival 402 rates compared to those with low 10-gene and hypoxia scores ( Fig. 5 hypoxia drove the upregulation of NHEJ-associated genes, PRKDC and XRCC6, in hepatoma cell 408 lines 37 . The authors proposed an interaction between PRKDC and the hypoxia-responsive 409 transcriptional activator, HIF-1α, hence suggesting that tumor hypoxia may lead to increase in 410 NHEJ. Tumor cells within their 3D space are subjected to differential levels of oxygen over time 411
and chronic exposures to these fluctuating conditions could result in very different biological 412 outcomes. In vitro studies retain a significant caveat as many hypoxia assays are carried out 413 short term using constant, predefined oxygen tensions. Although further work is needed to 414 ascertain the clinical relevance of these findings, our results clearly demonstrate that the 415 integration of hypoxia assessment in molecular stratification using the 10-gene signature 416 We reasoned that the expression patterns of DNA repair genes would positively correlate with 421 genes involved in cell cycle progression since lesions could be repaired more effectively to 422 prevent cell cycle arrest (Fig. 6A ). Enhanced DNA repair ability may also confer tumor cells with 423 growth advantage. Consistent with this hypothesis, differential expression analyses between 424 patients with high versus low 10-gene scores revealed an enrichment of ontologies involved in 425 growth stimulation as a consequence of increased DNA repair gene expression ( Fig. 6B) . 426
Enrichment of biological pathways involved in cell cycle, mitosis, cell division and DNA 427 replication implied that the shorter life expectancy in patients with high 10-gene scores could 428 in part be explained by an overproliferation phenotype commonly present in more aggressive 429 tumors. 430
431
In summary, we developed a prognostic signature involving DNA repair genes and confirmed 432 its utility as a powerful predictive marker for six cancer types. Although not currently afforded 433 by this work due to its retrospective nature, it will be useful to determine if the signature can 434 predict response to radiotherapy and chemotherapy in future research. While prospective 435 validation is warranted, we would expect, based on our encouraging retrospective data, that 436 the signature can guide decision making and treatment pathways. The confirmation of this 437 hypothesis by a clinical trial using the 10-gene signature to select patients that would benefit 438 from treatment with adjuvant DNA repair inhibitors could have a substantial impact on 439 treatment outcomes. were performed on patients categorized according to tumor TNM stages that were further 564 stratified using the 10-gene signature. The signature successfully identified patients at higher 565 risk of death in all TNM stages. P values were determined from the log-rank test. TNM: tumor, 566 node, metastasis. 567 and genes involved in cell cycle progression, while negative correlations were observed with 584 genes involved in cell cycle arrest. Heatmaps were generated using the R pheatmap package. 585
Cell cycle genes were depicted on the y-axis and the 10 signature genes on the x-axis. ( 
B) 586
Patients were median-stratified into low-and high-score groups using the 10-gene signature 587 for differential expression analyses. Enrichment of GO and KEGG pathways associated with 588 differentially expressed genes were depicted for all six cancers. (C) Investigation of the 589 relationship between a gene involved in cell cycle checkpoint regulation, TP53, and the 590 signature. Patients were categorized into four groups based on their TP53 mutation status and 591 10-gene scores for Kaplan-Meier analyses. P values were determined from the log-rank test. 592 593 166  131  106  88  63  46  99  81  69  53  42  27  163  143  115  94  69  51  96  80  65  54 51  46  35  23  16  11  133  111  84  59  47  30  26  24  20  17  12  10  158  140  102  71  58  45 Number at risk Figure S3 
